Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study.

Autor:	Antoon JW; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Amarin JZ; Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Epidemiology Doctoral Program, Vanderbilt University, Nashville, Tennessee, USA., Hamdan O; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Stopczynski T; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Stewart LS; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Michaels MG; UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA., Williams JV; UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA., Klein EJ; Seattle Children's Research Institute, Seattle, Washington, USA., Englund JA; Seattle Children's Research Institute, Seattle, Washington, USA., Weinberg GA; University of Rochester School of Medicine and Dentistry, Rochester, New York, USA., Szilagyi PG; University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.; UCLA Mattel Children's Hospital and Department of Pediatrics, University of California at Los Angeles, Los Angeles, California, USA., Schuster JE; Children's Mercy Hospital and University of Missouri-Kansas City, Kansas City, Missouri, USA., Selvarangan R; Children's Mercy Hospital and University of Missouri-Kansas City, Kansas City, Missouri, USA., Harrison CJ; Children's Mercy Hospital and University of Missouri-Kansas City, Kansas City, Missouri, USA., Boom JA; Texas Children's Hospital and Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA., Sahni LC; Texas Children's Hospital and Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA., Muñoz FM; Texas Children's Hospital and Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA., Staat MA; Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Schlaudecker EP; Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Chappell JD; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Clopper BR; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Moline HL; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Campbell AP; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Spieker AJ; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Olson SM; Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Halasa NB; Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Dec 17. Date of Electronic Publication: 2024 Dec 17.
DOI:	10.1093/cid/ciae573
Abstrakt:	Background: Guidelines state that all hospitalized children with suspected or confirmed influenza receive prompt treatment with influenza-specific antivirals. We sought to determine the frequency of, and factors associated with, antiviral receipt among hospitalized children. Methods: We conducted active surveillance of children presenting with fever or respiratory symptoms from 1 December 2016 to 31 March 2020 at 7 pediatric medical centers in the New Vaccine Surveillance Network. The cohort consisted of children hospitalized with influenza A or B confirmed by clinical or research testing. The primary outcome was frequency of antiviral receipt during hospitalization. We used logistic regression to obtain adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for factors associated with antiviral receipt. Results: A total of 1213 children with laboratory-confirmed influenza were included. Overall, 652 children (53.8%) received an antiviral. Roughly 63.0% of children received clinical influenza testing. Among those with clinical testing, 67.4% received an antiviral. Factors associated with higher odds of antiviral receipt included hematologic (aOR = 1.76; 95% CI = 1.03-3.02) or oncologic/immunocompromising (aOR = 2.41; 95% CI = 1.13-5.11) disorders, prehospitalization antiviral receipt (aOR = 2.34; 95% CI = 1.49-3.67), clinical influenza testing (aOR = 3.07; 95% CI = 2.28-4.14), and intensive care unit admission (aOR = 1.53; 95% CI = 1.02-2.29). Symptom duration >2 days was associated with lower odds of antiviral treatment (aOR = 0.40; 95% CI = .30-.52). Antiviral receipt varied by site with a 5-fold difference across sites. Conclusions: Almost half of children hospitalized with influenza did not receive antivirals. Additional efforts to understand barriers to guideline adherence are crucial for optimizing care in children hospitalized with influenza. Competing Interests: Potential conflicts of interest. J. W. A. previously served as a member of the AstraZeneca Scientific Advisory Board. G. A. W. has received honoraria from Merck & Company for writing and revising chapters in the Merck Manual Electrophysiologic Studies. M. A. S. has received research funding from Pfizer and honoraria from Sanofi Pasteur for vaccine consultation. J. A. E. reports work as a consultant to AbbVie, AstraZeneca, Meissa Vaccines, Pfizer, Moderna, and Sanofi Pasteur and research to support their university from AstraZeneca, GSK, Merck, and Pfizer. M. G. M. reports research to support their university from Merk Sharpe & Dohme and a nonfinancial research grant from Viracor. F. M. M. reports work as a consultant for Moderna, GSK, AstraZeneca, Sanofi, Novavax, and Merck; serving on the data and safety monitoring boards for Pfizer, Moderna, the National Institutes of Health (NIH), Meissa, and Dynavax; and grant and research support from Pfizer, Gilead, NIH, and CDC. J. E. S. reports work as a consultant at the Association of American Medical Colleges. J. V. W. previously served as a member of the Quidel Scientific Advisory Board and on an independent data monitoring committee for GSK. S. M. O. reports travel support from the Gates Foundation. N. B. H. received grant support from Sanofi and Quidel, receives current grant support from Merck, and served on an advisory board for CSL Seqirus. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu